Financial reports
10-K
2020 FY
Annual report
22 Mar 21
10-Q
2020 Q3
Quarterly report
3 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
26 Feb 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
Current reports
8-K
Completion of Acquisition or Disposition of Assets
16 Apr 21
8-K
Other Events
15 Apr 21
8-K
Amgen to Acquire Five Prime Therapeutics for Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class
4 Mar 21
8-K
Results of Operations and Financial Condition
15 Jan 21
8-K
Other Events
15 Jan 21
8-K
Five Prime Announces Closing of Upsized Public Offering of Common Stock
17 Nov 20
8-K
Five Prime Announces Pricing of Upsized Public Offering of Common Stock
13 Nov 20
8-K
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates
10 Nov 20
8-K
Five Prime Therapeutics Reports Third Quarter 2020 Results
3 Nov 20
8-K
Five Prime to Present First Pre-clinical Data of Anti-CCR8 Antibody FPA157
2 Nov 20
Registration and prospectus
15-12B
Securities registration termination
26 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 21
POS AM
Prospectus update (post-effective amendment)
16 Apr 21
Proxies
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
3 Apr 20
DEF 14A
Definitive proxy
29 Apr 19
PRE 14A
Preliminary proxy
12 Apr 19
DEF 14A
Definitive proxy
30 Mar 18
DEF 14A
Definitive proxy
31 Mar 17
DEF 14A
Definitive proxy
30 Mar 16
DEF 14A
Definitive proxy
24 Apr 15
DEF 14A
Definitive proxy
4 Apr 14
Other
EFFECT
Notice of effectiveness
22 Apr 21
CT ORDER
Confidential treatment order
5 Aug 20
CT ORDER
Confidential treatment order
3 Aug 20
SEC STAFF
SEC staff action: Order
3 Mar 20
SEC STAFF
SEC staff action: Order
12 Feb 20
EFFECT
Notice of effectiveness
23 Aug 19
CORRESP
Correspondence with SEC
20 Aug 19
CT ORDER
Confidential treatment order
2 Aug 19
CT ORDER
Confidential treatment order
2 Aug 19
CT ORDER
Confidential treatment order
2 Aug 19
Ownership
SC 13G/A
Rock Springs Capital Management LP
15 Feb 22
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
17 May 21
4
Francis Willard Sarena
19 Apr 21
4
David V Smith
19 Apr 21
4
Helen Louise Collins
19 Apr 21
4
David White
19 Apr 21
4
WILLIAM R RINGO
19 Apr 21
4
FRANKLIN M BERGER
19 Apr 21
4
Kapil Dhingra
19 Apr 21
4
Peder Jensen
19 Apr 21